AMG 232

Drug Profile

AMG 232

Alternative Names: AMG-232

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; GlaxoSmithKline; National Cancer Institute (USA); Vanderbilt University Medical Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Acute myeloid leukaemia; Glioblastoma; Multiple myeloma; Solid tumours
  • Preclinical Adenocarcinoma

Most Recent Events

  • 05 Sep 2017 Amgen completes a phase I trial for Solid tumours and Multiple myeloma (Late-stage disease, Second-line therapy or greater) in USA, France and Netherlands (PO) (NCT01723020)
  • 31 Jul 2017 Amgen completes a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy, Combination therapy) in USA (PO) (NCT02016729)
  • 19 Jul 2017 National Cancer Institute plans a phase Ib trial for Soft tissue sarcoma (Neoadjuvant therapy) in USA (NCT03217266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top